Mauna Kea Technologies SA announced that it has received 2.3 million in a round of funding on May 31, 2023. The transaction included participation from new investor Tasly Pharmaceutical Group Co., Ltd.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.388 EUR | -0.51% | 0.00% | -17.62% |
Apr. 25 | Mauna Kea Technologies SA Provides Sales Guidance for the Year 2024 | CI |
Apr. 03 | Mauna Kea: first Italian center for Cellvizio | CF |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
15.41 CNY | +0.33% | +0.52% | 3.15B | ||
0.388 EUR | -0.51% | 0.00% | 25.62M | ||
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-17.62% | 25.62M | |
-12.42% | 19.08B | |
-44.70% | 2.65B | |
+18.15% | 1.87B | |
-0.58% | 1.61B | |
+25.36% | 1.21B | |
-8.67% | 1.02B | |
-20.89% | 905M | |
-4.42% | 716M | |
-17.15% | 682M |
- Stock Market
- Equities
- ALMKT Stock
- News Mauna Kea Technologies
- Mauna Kea Technologies SA announced that it has received €2.3 million in funding from Tasly Pharmaceutical Group Co., Ltd